4 OTC Rally Stocks Showing Strength (LOBEF, HLYK, GCLY ADXS)

Last week, the markets gave us plenty of volatility to navigate through. But ultimately, that turbulence resulted in a stock market upswing. During the Friday session, major indexes regained lost ground from the end of 2022.

Investors don’t seem to have been concerned about the fact that this was another short week, given how things have turned out so far. Some of the smaller and more speculative stocks start to get their share of investor activity as investors pour money into the broader market.

Here are four stocks that have put together a strong week of trading thus far; keep an eye out to see if these will rally to continue to finish the week strong.

Lobe Sciences LTD. (OTC: LOBEF) (CSX: LOBE) is a life sciences biotechnology company focused on psychedelic medicines. The company works to research and develop drugs that use psychedelic compounds, as well as invent new devices and methods to deliver drugs that will improve mental health and wellness.

At the moment, the company has filed for five provisional patents, done pre-clinical studies, and is working on an engineering design for a drug delivery device.

In an update to shareholders released on January 18th, Philip Young, chairman and CEO of the company, stated, “2022 was a productive year for Lobe Sciences.” “We increased our intellectual property portfolio with several new chemical entities (NCEs) derived from well-known psychedelic compounds, adding two of these, L-130 and L-131, to our development program.”

The year ahead looks to be even more important, as CEO Young added, “By year’s end, we should have two active INDs, one of which may be designated as an orphan drug, and an ongoing Phase II trial assessing L-130 as a therapeutic to treat a refractive neurological disorder.” “We will release details of each of these trials and the indication being treated as our patents are published.”

LOBEF has a chance to make significant strides this year given that experts anticipate that the market for psychedelic medicines will expand even further in 2023. As the company moves forward with clinical testing, astute investors should keep a close eye on this stock as there is a good chance for significant updates throughout the year.

HealthLynked Corp. (OTC: HLYK) provides a solution for both patients and providers to improve healthcare through the efficient exchange of medical information. The HealthLynked Network is a cloud-based platform that allows members to better connect with their healthcare providers.

In-network providers will benefit from the ability to use the HealthLynked patent-pending patient access hub (“PAH”) for patient analytics. Other advantages for preferred providers include HLYK marketing tools for connecting with active and inactive patients to improve patient retention, access to more accurate and current patient information, more efficient online scheduling, and filling last-minute cancellations using the company’s “real-time appointment scheduling,” all within its mobile application.

On December 27, 2022, HLYK announced the initial results of its Medical Membership and Concierge programs at their subsidiary, the Naples Center for Functional Medicine. The company found that, to date, over 50% of patients have decided to join the HealthLynked Network, with 79% participation in the medical membership and concierge programs after just 1 year of offering them to patients.

The stock has had a favorable week so far, finishing up 40.78% on Wednesday at $0.14.

Advaxis, Inc. (OTC: ADXS) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins.

Last week, the company announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate. According to ADXS, “ADXS-504 has been well tolerated with no serious adverse events reported. Four out of six patients treated are still in study, and PSA values are being followed up.”

The trial is currently expanding enrollment at the second dose level by up to six additional patients for a total of nine patients.

Following the news, the stock has been on a tear, rising from $1.60 last Friday all the way to closing at $2.95 on Wednesday’s trading session. On Wednesday alone, the stock saw a 33.14% jump.

GainClients, Inc. (OTC: GCLT) provides technology solutions to the real estate industry. The company offers SikkU software services, which include lead generation and marketing services integrated with local realtor association data, all based on a networking platform. GCLT provides tools that connect together into a mini-network of various participants in the home buying and selling process.

On the 18th of January, GCLT announced that they had completed a connection for a new client that included connecting with a prominent solution provider in the financial sector, Jack Henry & Associates, Inc. One of the main clients of Jack Henry & Associates is Independent Bank in TX.

GainClients reports that with the addition of their new accounts, they now serve 69 offices in four states and collected 4,000 earnest money deposits in Fiscal Year 2022 alone.

The stock has strung together a solid few days of trading, capping things off today with a $61.43% price rise. Keep an eye on this stock throughout the end of the week to see if the momentum continues.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated via wire transfer by Lightwave Partners to produce and syndicate content related to LOBEF. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.